Clinical trials
Active, not recruiting Lymphoproliferative Disorders trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 19 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| UNC Lineberger Comprehensive Cancer Center | 3 |
| Baylor College of Medicine | 2 |
| Center for International Blood and Marrow Transplant Research | 2 |
| Acerta Pharma BV | 1 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Cellectar Biosciences, Inc. | 1 |
| Georgetown University | 1 |
| M.D. Anderson Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoproliferative Disorders | 19 |
| Neoplasms | 10 |
| Immune System Diseases | 9 |
| Lymphoma | 9 |
| Lymphoma, Non-Hodgkin | 9 |
| Immunoproliferative Disorders | 7 |
| Lymphatic Diseases | 7 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 |
| Myelodysplastic Syndromes | 6 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.